JP2025502240A - がんの治療のための二環式トリアジン誘導体 - Google Patents

がんの治療のための二環式トリアジン誘導体 Download PDF

Info

Publication number
JP2025502240A
JP2025502240A JP2024541916A JP2024541916A JP2025502240A JP 2025502240 A JP2025502240 A JP 2025502240A JP 2024541916 A JP2024541916 A JP 2024541916A JP 2024541916 A JP2024541916 A JP 2024541916A JP 2025502240 A JP2025502240 A JP 2025502240A
Authority
JP
Japan
Prior art keywords
trifluoromethyl
group
salt
cancer
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502240A5 (https=
Inventor
テーデ、カイ
バッハグラバー、フィリップ
ジーマイスター、ゲルハルト
シュタイゲマン、パトリック
マルグレート ヴェングナー、アンチェ
ベマー、ウルフ
リーナウ、フィリップ
ヴェスターマン、フランク
グリム、ハノ
ハーブスト－ノールツィ、フリーデリーケ
ディーター、ゼバスティアン
クレト、ジーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of JP2025502240A publication Critical patent/JP2025502240A/ja
Publication of JP2025502240A5 publication Critical patent/JP2025502240A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024541916A 2022-01-11 2023-01-06 がんの治療のための二環式トリアジン誘導体 Pending JP2025502240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150829 2022-01-11
EP22150829.4 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025502240A true JP2025502240A (ja) 2025-01-24
JP2025502240A5 JP2025502240A5 (https=) 2026-01-06

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541916A Pending JP2025502240A (ja) 2022-01-11 2023-01-06 がんの治療のための二環式トリアジン誘導体

Country Status (9)

Country Link
US (1) US20250066370A1 (https=)
EP (1) EP4463458A1 (https=)
JP (1) JP2025502240A (https=)
KR (1) KR20240134962A (https=)
CN (1) CN118541372A (https=)
AU (1) AU2023207765A1 (https=)
CA (1) CA3246440A1 (https=)
IL (1) IL313835A (https=)
WO (1) WO2023135057A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
WO2021176045A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
KR20240134962A (ko) 2024-09-10
WO2023135057A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
CN118541372A (zh) 2024-08-23
CA3246440A1 (en) 2023-07-20
AU2023207765A1 (en) 2024-07-04
US20250066370A1 (en) 2025-02-27
IL313835A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EP3532474B1 (en) 4,5-annulated 1,2,4-triazolones
EP3959202A1 (en) Acyl sulfonamides for treating cancer
WO2018024602A1 (en) 2,7-diazaspiro[4.4]nonanes
EP3390387B1 (en) Heteroarylbenzimidazole compounds
US20230106032A1 (en) Imidazotriazines acting on cancer via inhibition of cdk12
EP4322962A1 (en) Phosphorus derivatives as novel sos1 inhibitors
WO2022081842A1 (en) Substituted acyl sulfonamides for treating cancer
WO2017005674A1 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
EP3645531A1 (en) Thiazole compounds useful as prmt5 inhibitors
WO2018104307A1 (en) Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
WO2020126968A2 (en) Urea derivatives
US20230117034A1 (en) Pyrazolotriazines
US20250170136A1 (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2017202817A9 (en) [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones
EP4114837A1 (en) Pyrazolopyrazines acting on cancers via inhibition of cdk12
JP2025502240A (ja) がんの治療のための二環式トリアジン誘導体
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
WO2018114670A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
WO2020157236A1 (en) Pyridyl substituted dihydrooxadiazinones
EP3555067A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251222